Angiogenesis is the formation of new blood vessels. Tumors usurp the natural process of angiogenesis in order to build blood vessels for cancerous growth. By preventing blood vessel formation, anti-angiogenesis drugs starve tumors and inhibit their progression.

Verseon has developed several candidate compounds that show strong potency in cell-based and ex vivo assessments of inhibition of angiogenesis without significant cytotoxicity. Tests have confirmed that these compounds do not inhibit vascular endothelial growth factor receptors and other major kinases typically involved in angiogenesis, distinguishing them from conventional angiogenesis therapies.

Our current drug portfolio spans four separate therapeutic areas, all with unmet (or poorly met) medical needs


Current Pipeline

First-in-class oral anticoagulants for cardiovascular indications

Kallikrein inhibitors for the treatment of diabetic macular edema

Kallikrein inhibitors for the treatment of hereditary angioedema

Novel angiogenesis inhibitors for the treatment of solid tumors